Skip to main content
. 2022 May 18;28(18):3929–3939. doi: 10.1158/1078-0432.CCR-21-3304

Figure 2.

Figure 2. Overview of active mRNA-based immunotherapeutic strategies. Left, LNP-antigen mRNA vaccine delivered systemic or locally, followed by antigen expression resulting in T-cell priming and eventually cancer cell killing. Right, monocytes or hematopoietic progenitor cells are isolated from blood, further cultured, and differentiated into DCs. mRNA is then used to load the DCs ex vivo with tumor antigens. The modified DCs are administered to patients, where they will prime T cells resulting eventually in the killing of cancer cells. Adapted from an image created with BioRender.com.

Overview of active mRNA-based immunotherapeutic strategies. Left, LNP-antigen mRNA vaccine delivered systemic or locally, followed by antigen expression resulting in T-cell priming and eventually cancer cell killing. Right, monocytes or hematopoietic progenitor cells are isolated from blood, further cultured, and differentiated into DCs. mRNA is then used to load the DCs ex vivo with tumor antigens. The modified DCs are administered to patients, where they will prime T cells, eventually resulting in the killing of cancer cells. Adapted from an image created with BioRender.com.